A note for UK readers

This page explains United States’s system. Its licences, funding rules and prescribing criteria do not determine access in the UK.

Does Medicare now cover every weight-management prescription?

No. The GLP-1 Bridge is a separate, temporary programme for qualifying beneficiaries and specified products; eligibility and prior authorisation still apply.

Use the US product name

FDA distinguishes Zepbound for weight management from Mounjaro for type 2 diabetes, although both contain tirzepatide. Check the current label for the exact product and formulation rather than importing a brand's indication from another country.

Identify the payment route

CMS launched the Medicare GLP-1 Bridge in July 2026 outside normal Part D payment arrangements. Certain other approved uses remain within Part D. The correct route depends on diagnoses and programme rules, not simply a request to lose weight.

A quoted price needs context

Ask whether a quote is an insured copayment, cash price or conditional offer. Confirm the pharmacy, formulation, quantity, clinical fees and any authorisation requirement. One advertised amount cannot represent every US patient's cost.

Bring US headlines back to UK rules

Medicare is a US programme and provides no NHS entitlement. US brand names and approved indications can also differ from UK ones. A dollar copayment reported in the news is therefore not a benchmark for a UK private prescription or care package.

Keep these four questions separate

Access

US product and indication rules differ from UK rules

Funding

Insurance rules plus eligible Medicare Bridge access

Cost context

USD cash prices and copayments are not UK prices

Regulatory source

FDA

Compare health systems ↗
Follow the evidence

Sources & further reading

Sources checked . These links support the information above; they do not imply endorsement of this website.

  1. FDA: Zepbound approval and distinction from Mounjaro
  2. CMS: Medicare GLP-1 Bridge
  3. CMS: detailed Bridge and Part D eligibility rules
A note on this guide

Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.

Read our editorial standards →